M&A In Biopharma Therapeutics & Platforms – Q2 2023

by Aug 4, 2023Analysis, M&A

Biopharma M&A activity in Q2 2023 picked up as the number of therapeutics and discovery platform company acquisitions tracked higher. The second quarter of 2023 saw 27 M&A deals for a total upfront of $27.4 billion or $28.1 billion when counting contingent payments. This follows a higher-value Q1 2023, which had 26 deals for $50.1 billion or $51.4 billion with contingencies. Pfizer announcing its acquisition of Seagen raised the Q1 2023 total significantly.

Biopharma Therapeutics and Platform M&A - DealForma

Biopharma Therapeutics and Platform M&A. Total M&A Upfront Cash & Equity - Biopharma TX - DealForma


Biopharma Therapeutics & Platforms Vs Other Life Sciences

M&A - Biopharma Tx vs. Other Life Sciences. DealForma

Biopharma therapeutics and discovery platform M&A peaked in 2019 at $203.9 billion with BMS/Celgene, then the annual total values fell every year through 2022 at $85.8 billion. The first half of 2023 is looking positioned to put full-year 2023 much higher. A recent Stifel report had the 2023 estimate at above $150 billion to set 2023 as the third highest annual value since 2008. This year’s total biopharma M&A deal value was at $80.9 billion as of June 30, 2023.

M&A - Biopharma Tx vs. Other Life Sciences. Number of M&A Deals - DealForma


M&A – Top Technologies Since 2022

M&A, Top Technologies 2002-2023 YTD - DealForma

Biologics company acquisitions topped the list of technologies in M&A from 2022 to 2023 YTD with 53 deals and a substantial total M&A value of $76 billion. Small molecule-focused company acquisitions ranked second with 69 deals totaling $58.8 billion.


Top 5 Biopharma M&A Deals Of Q2 2023
  • Merck completed its acquisition of Prometheus Biosciences in June 2023. Prometheus’ lead assets were Phase II PRA-023 for Ulcerative Colitis and Crohn’s Disease, Phase I PRA-052, and various preclinical therapies. Prometheus shareholders received $200.00 per share in cash at a one-day premium of 75% and total of $10.8 billion.
  • Astellas Pharma acquired Iveric Bio in April 2023. The acquisition included Iveric Bio’s assets, such as Phase III Avacincaptad pegol, preclinical therapies, and research-stage candidates. The total equity value of the acquisition amounted to $5.9 billion, achieved through the allocation of 148.2 million shares of Iveric’s common stock at $40.00 per share in cash, representing a one-day premium of 22%.
  • Novartis announced its acquisition of Chinook Therapeutics in June 2023. Chinook’s lead assets include Phase III Atrasentan and Phase II BION-1301. Chinook shareholders will receive $40.00 per share at a one-day premium of 67% for a total of $3.2 billion. Additionally, shareholders can receive up to $300 million through regulatory milestones.
  • Eli Lilly is set to acquire DICE Therapeutics. DICE shareholders will receive an upfront payment of $48.00 per share in cash at a one-day premium of 42% and a total upfront value of $2.4 billion.
  • GSK acquired BELLUS Health, a late-stage biopharmaceutical company focused on refractory chronic cough. The acquisition involved a payment of $2 billion, equivalent to $14.75 per share of BELLUS’ common stock in cash at a one-day premium of 103%.



Licensing Deals


Funding Rounds




Company Profiles


Other Deals


Drug Sales Figures

All of this by stage, disease indication, modality, target...

More Research by DealForma

Neurology Venture Activity Through Q2 2023

Neurology Venture Activity Through Q2 2023

Quarterly venture investment activity into neurology focused biopharma companies is back to pre-2020 level. This is no surprise given the investment slowdowns across all therapy area and broader life sciences. The drop seems to have stabilized however, and emerging...